Nama's AI scorecard currently rates Moderna Sell (3.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does MRNA report earnings?

Moderna's next scheduled report is on Feb 12, 2027. Analysts expect EPS of -$3.08.

What is the MRNA price target?

The median analyst price target from 19 analysts is $125.00, with a range of $45.00 – $251.00.

Is MRNA Shariah compliant?

Nama's AAOIFI-style screen reads Moderna as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Moderna (MRNA)

Healthcare · Biotechnology · NASDAQ

S&P 500Nasdaq-100

Moderna (MRNA) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $101.48B and a free-cash-flow yield of -2.1%. Over the most recent reported fiscal year, revenue declined 39.9%. Nama's AI scorecard rates it Sell, 3.2 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 3.2/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Leading · +707.6% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-32.5%

How far the last close sits under the highest price of the past five years.

Market cap	$101.48B
Trailing P/E	—
Price / book	15.0
Price / sales	45.5
FCF yield	-2.1%
Dividend yield	—
Gross margin	22.8%
Operating margin	-150.2%
Net margin	-142.6%
Revenue growth (YoY)	-39.9%
Revenue growth (3-yr annual)	-53.3%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.1
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

MRNA earnings

Next report: Feb 12, 2027 (Q4 2026, EPS estimate -$3.08). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 6, 2026	$0.38	-$1.25	+130.4%	—
Q2 2026	Jul 31, 2026	-$1.97	-$2.06	+4.4%	$143.00M
Q1 2026	Apr 30, 2026	-$3.40	-$3.88	+12.4%	$389.00M
Q4 2025	Feb 13, 2026	-$2.11	-$2.64	+20.1%	$676.00M

MRNA analyst price target

Median target $125.00 from 19 analysts, ranging $45.00 – $251.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9
ROIV	Roivant Sciences	$28.08B	—

Explore live MRNA data on Nama Insights →

Recent Congressional trades

Moderna trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Maria Elvira Salazar	House	Sell	$1,001 - $15,000	Oct 7, 2026
Maria Elvira Salazar	House	Sell	$1,001 - $15,000	Sep 9, 2026
Rob Bresnahan	House	Sell	$1,001 - $15,000	May 8, 2025
Rob Bresnahan	House	Buy	$1,001 - $15,000	Mar 27, 2025
Julie Johnson	House	Sell	$1,001 - $15,000	Feb 12, 2025
Josh Gottheimer	House	Sell	$1,001 - $15,000	Mar 7, 2024
Josh Gottheimer	House	Sell	$1,001 - $15,000	Oct 15, 2023
Daniel Goldman	House	Sell	$50,001 - $100,000	Aug 13, 2023

MRNA FAQ

Is MRNA a buy?: Nama's AI scorecard currently rates Moderna Sell (3.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does MRNA report earnings?: Moderna's next scheduled report is on Feb 12, 2027. Analysts expect EPS of -$3.08.
What is the MRNA price target?: The median analyst price target from 19 analysts is $125.00, with a range of $45.00 – $251.00.
Is MRNA Shariah compliant?: Nama's AAOIFI-style screen reads Moderna as Not Shariah Compliant. At least one of the three ratios or the industry test failed.